Data protection Impressum

Biotech

Cytiva’s recent move underlines Western Switzerland’s Health Valley region's growing significance as a hub for healthcare technology.

Cytiva’s strategic expansion in Western Switzerland’s Health Valley

11 December 2023

Siegfried’s Evionnaz site currently employs 380 professionals and is in the process of constructing a new R&D building, which is set to double the company's development capacity and create around 40 new jobs.

Siegfried, a Swiss leader taking innovations to industrial scale for the pharmaceutical industry

4 December 2023

LAGOSTA specializes in the sustainable farming of the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs.

Vaud-based LAGOSTA and global giant Merck collaborate on chitosan distribution

2 November 2023

This strategic partnership will allow Fapon to research, develop, make, and sell PSP materials and test solutions using the chemiluminescence immunoassay (CLIA) in the Chinese market.

Abionic and Lascco partner with Fapon for sepsis diagnosis in China

2 November 2023

Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres.

EPFL and Novochizol to collaborate on designing more efficient immunotherapies

2 November 2023

The Institute of Tissue Medicine and Pathology of the University of Bern covers the entire width of the morphological and molecular diagnostics of tissue samples. | © University of Bern

A new gel offers targeted relief for ulcerative colitis patients

2 November 2023

Located in Lonza's Visp industry park, Bacthera's MC4a Center of Excellence covers 12,000 square meters, featuring three manufacturing floors with one dedicated to SER-109 production.

Bacthera’s Visp plant aims to revolutionize microbiome-based treatments

30 October 2023

Established in the canton of Valais since 1989, Debiopharm is building a full-scale research and innovation campus in Martigny.

Debiopharm invests CHF 30 million in Valais amidst workforce surge

26 October 2023

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

17 October 2023

Mimix’s objective, as outlined in its strategic vision, is to introduce this wound care product to the US market by the second half of 2024.

Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment

17 October 2023

1 … 8 9 10 11 12 13 14 15 16 … 22